# A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets

> **NCT03225352** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 12 (actual)

## Conditions studied

- Moderate Pain

## Interventions

- **DRUG:** 500 mg acetylsalicylic acid (Aspirin, BAYE4465)
- **DRUG:** 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)
- **DRUG:** 400 mg ibuprofen(Nurofen)
- **DRUG:** 400 mg ibuprofen (Dolormin Extra)

## Key facts

- **NCT ID:** NCT03225352
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2017-10-07
- **Final completion:** 2017-10-16
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03225352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03225352, "A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03225352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*